Organon & Co traded at $5.70 this Monday March 30th, decreasing $0.14 or 2.40 percent since the previous trading session. Looking back, over the last four weeks, Organon & Co lost 20.72 percent. Over the last 12 months, its price fell by 61.77 percent. Looking ahead, we forecast Organon & Co to be priced at 5.66 by the end of this quarter and at 5.17 in one year, according to Trading Economics global macro models projections and analysts expectations.
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women''s health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.